Ac­celeron drops a de­vel­op­ment pro­gram as #2 drug fails to spark func­tion­al ben­e­fits in pa­tients with a rare neu­ro­mus­cu­lar ail­ment

Ac­celeron is scrap­ping a mus­cu­lar dy­s­tro­phy de­vel­op­ment pro­gram un­der­way for its num­ber 2 drug in the pipeline af­ter pour­ing over some failed mid-stage sec­ondary da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.